Merck Snags Yet Another Indication for This Drug Combo

On Dec. 27, Merck (NYSE: MRK) announced that Keytruda secured another approval from Japan's Ministry of Health, Labour and Welfare (MHLW) in combination with Eisai's (OTC: ESALY) Lenvima. The agency gave the combo the green light to treat patients with unresectable, advanced, or recurrent endometrial carcinomas that progressed after chemotherapy.

What led the MHLW to authorize Keytruda and Lenvima for certain endometrial cancer patients? And what level of sales could this mean for the pharma stock? Let's go over the efficacy of the drug pairing and the endometrial cancer market in Japan to answer these questions.

Image source: Getty Images.

Continue reading

Source Fool.com